



## Program on Friday, 17 February 2017

08:00

### Oral Communications, Room Boston 1+2

Bleeding disorders - Basic science

Chairs:

**W.-A. Hassenpflug** (Hamburg, Germany)

**C. von Auer** (Mainz, Germany)

08:00

**Investigating the pathomolecular mechanisms an in-frame heterozygous von Willebrand factor large deletion in a von Willebrand disease patient with significant bleeding history**

H. Yadegari (Bonn, Germany)

N. Marquardt (Bonn, Germany)

V. Ivaskevicius (Bonn, Germany)

O. Rawley (Kingston, Canada)

L. Swystun (Kingston, Canada)

D. Lillicrap (Kingston, Canada)

J. Oldenburg (Bonn, Germany)

08:12

**Possible role of protein disulfide isomerase PDIA1 in mechanisms of von Willebrand disease type 3**

M. A. Brehm (Hamburg, Germany)

S. Vollmers (Hamburg, Germany)

T. Obser (Hamburg, Germany)

R. Schneppenheim (Hamburg, Germany)

08:24

**Synergistic effects of a procoagulant bispecific antibody and rescue therapy on thrombin generation - a potential safety risk?**

R. Hartmann (Vienna, Austria)

S. Knappe (Vienna, Austria)

B. Goldstein (Cambridge, United States)

B. Ewenstein (Cambridge, United States)

L. Valentino (Bannockburn, United States)

F. Scheifflinger (Vienna, Austria)

08:36

**Calcium binding sites of coagulation factor XIII (FXIII) A subunit and their functional relevance to the activation of FXIII A subunit**

S. Singh (Bonn, Germany)

C. Krettler (Frankfurt, Germany)

C. Reinhart (Frankfurt, Germany)

J. Dodt (Langen, Germany)

V. Ivaskevicius (Bonn, Germany)

J. Oldenburg (Bonn, Germany)

A. Biswas (Bonn, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

08:48

[Hemophilia macrophages exhibit specific defects relating to wound healing](#)

J. Pilch (Homburg, Germany)  
D. Lessig (Homburg, Germany)  
M. Bernard (Homburg, Germany)  
E. C. Schwarz (Homburg, Germany)  
H. Eichler (Homburg, Germany)  
L. M. Knowles (Homburg, Germany)

09:00

[Plasma derived FVIII concentrates induce neutrophil activation and neutrophil extracellular trap formation.](#)

B. E. Kehrel  
A. Bertling  
M. F. Brodde

08:00

[State of the Art, Room Montreal](#)

Pediatric Thrombosis

Chairs:

**M. Albisetti Pedroni** (Zurich, Switzerland)  
**R. Knöfler** (Dresden, Germany)

08:00

[Thrombophilia in pediatric cancer](#)

A. C. Chan (Hamilton, Canada)

08:25

[Thrombophilia screening in adolescents](#)

U. Nowak-Göttl (Kiel, Germany)

08:50

[Cerebral venous thrombosis in neonates, children and adolescents; results from the German pediatric surveillance unit for rare pediatric diseases \(ESPED\)](#)

S. Holzhauer (Berlin , Germany )  
K. Kentouche (Jena , Germany )  
A. Kruempel (Muenster, Germany )  
C. Heller (Frankfurt, Germany )  
R. Knoefler (Dresden , Germany )  
R. Straeter (Muenster , Germany )  
U. Nowak-Göttl (Kiel , Germany )



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

09:02

**Faster spatial fibrin clot formation in neonates than in adults.**

A. Schlagenhauf (Graz, Austria)

S. Pohl (Graz, Austria)

E. Zoehrer (Graz, Austria)

B. Leschnik (Graz, Austria)

H. Haidl (Graz, Austria)

S. Gallistl (Graz, Austria)

W. Muntean (Graz, Austria)

08:00

**Oral Communications, Room Shanghai 1+2**

Vascular Wall

Chairs:

**M. Gawaz** (Tuebingen, Germany)

**A. Zirlik** (Freiburg, Germany)

08:00

**Early atheroprotection through fostamatinib fails in established disease when local macrophage proliferation dominates lesion progression**

C. Härdtner (Freiburg, Germany)

A. Lindau (Freiburg, Germany)

B. Dufner (Freiburg, Germany)

N. Hoppe (Freiburg, Germany)

F. K. Swirski (Boston, USA)

P. Libby (Boston, USA)

C. S. Robbins (Toronto, Canada)

C. Bode (Freiburg, Germany)

A. Zirlik (Freiburg, Germany)

I. Hilgendorf (Freiburg, Germany)

08:12

**The role of the purinergic receptor P2X7 in the pathogenesis of atherosclerosis**

S. von Garlen (Freiburg, Germany)

A. Heidenreich (Freiburg, Germany)

P. Stachon (Freiburg, Germany)

J. Merz (Freiburg, Germany)

S. Geis (Freiburg, Germany)

B. Dufner (Freiburg, Germany)

N. Hoppe (Freiburg, Germany)

N. Anto Michel (Freiburg, Germany)

C. Bode (Freiburg, Germany)

M. Idzko (Freiburg, Germany)

A. Zirlik (Freiburg, Germany)



08:24

Targeting coagulation factor Xa with rivaroxaban reduces the onset and progression of atherosclerosis and enhances plaque stability in ApoE null mice

J. Posthuma (Maastricht, The Netherlands)  
J. Posma (Maastricht, The Netherlands)  
R. van Gorp (Maastricht, The Netherlands)  
A. Jaminon (Maastricht, The Netherlands)  
P. Leenders (Maastricht, The Netherlands)  
R. van Oerle (Maastricht, The Netherlands)  
S. Heitmeier (Wuppertal, Germany)  
L. Schurgers (Maastricht, The Netherlands)  
H. ten Cate (Maastricht, The Netherlands)  
H. Spronk (Maastricht, The Netherlands)

08:36

MicroRNA-23a regulates the tissue factor alternative splicing and thrombogenicity

T. Tabaraie (Berlin, Germany)  
M. Witkowski (Berlin, Germany)  
J. Friebe (Berlin, Germany)  
A. Doerner (Berlin, Germany)  
U. Landmesser (Berlin, Germany)  
U. Rauch (Berlin, Germany)

08:48

ADAMTS13 activity, neutrophil extracellular traps (NETs) and platelet functional capacity in patients with strokes from different etiologies.

H. S. Bölting (Muenster, Germany)  
M. Rumpf (Muenster, Germany)  
R. Dittrich (Muenster, Germany)  
J. Minnerup (Muenster, Germany)  
L. Schuengel (Muenster, Germany)  
M. F. Brodde (Muenster, Germany)  
M. Ritter (Muenster, Germany)  
B. E. Kehrel (Muenster, Germany)

09:00

The cross talk between coagulation cascade and endothelial cells in a porcine limb ischemia reperfusion injury model and the protective role of C1-INH

M. Abdelhafez (Bern, Switzerland)  
J. Shaw (Bern, Switzerland)  
D. Sutter (Bern, Switzerland)  
J. Schnider (Bern, Switzerland)  
H. Jenni (Bern, Switzerland)  
E. Voegelin (Bern, Switzerland)  
M. Constantinescu (Bern, Switzerland)  
R. Rieben (Bern, Switzerland)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

08:00

## State of the Art, Room Singapore

### Aging with Hemophilia

Chairs:

**A. Huth-Kühne** (Heidelberg, Germany)

**W. Schramm** (Munich, Germany)

08:00

### Management of cardiovascular disease in aging patients with hemophilia

R. Schutgens (Utrecht, The Netherlands)

08:25

### Treatment of hepatitis C - what the hemostasiologist should know

J.-F. Dufour (Bern, Switzerland)

08:50

### Value of factor prophylaxis in elderly patients with hemophilia

J. Oldenburg (Bonn, Germany)

08:00

## Oral Communications, Room Sydney

### Venous Thrombosis

Chairs:

**J. Beyer-Westendorf** (Dresden, Germany)

**S. Schellong** (Dresden, Germany)

08:00

### DOACs dose adherence during initial and long term VTE management. Practical implications, findings from the RIETE registry.

E. Papadakis (Thessaloniki, Greece)

J. Trujillo-Santos (Murcia, Spain)

P. Di Micco (Naples, Italy)

F. Dentali (Varese, Italy)

J.-A. Diaz-Peromingo (Santiago de Compostela, Spain)

M.-J. Nunez (Pontevedra, Spain)

I. Canas (Barcelona, Spain)

D. Mastroiacovo (Avezzano, Italy)

M.-S. De Sousa (Vila Nova de Gaia, Portugal, 10Badalona, Spain)

A. Banti (Thessaloniki, Greece)

M. Monreal



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

08:12

Patterns of VTE treatment with rivaroxaban in cancer patients – Results of the prospective Dresden NOAC registry (NCT01588119)

S. Endig (Dresden, Germany)  
S. Marten (Dresden, Germany)  
A. Reitter (Dresden, Germany)  
K. Daschkow (Dresden, Germany)  
L. Tittl (Dresden, Germany)  
J. Beyer-Westendorf (Dresden, Germany)

08:24

Survival and recurrent venous thromboembolism in 834 subjects after a first episode of isolated distal or proximal deep vein thrombosis without pulmonary embolism

S. Barco (Mainz, Germany)  
M. Corti (Pavia, Italy)  
A. Trincheri (Mainz, Germany)  
C. Picchi (Pavia, Italy)  
S.V. Konstantinides (Mainz, Germany)  
C. Ambaglio (Pavia, Italy)  
F. Dentali (Varese, Italy)  
M. Barone (Pavia, Italy)

08:36

Clinical outcomes of a management strategy consisting of tailored anticoagulant treatment based on residual vein thrombosis: contemporary data

M. Nagler (Bern, Switzerland)  
H. ten Cate (Maastricht, The Netherlands / Maastricht, The Netherlands)  
M. Prins (Maastricht, The Netherlands)  
A. ten Cate-Hoek (Maastricht, The Netherlands)

08:48

Innate effector-memory T cell activation regulates post-thrombotic vein wall inflammation and thrombus resolution

F. Shahneh  
N. Luther  
M. Brähler  
F. Krebs  
S. Jäckel  
P. Wenzel  
K. Schäfer  
C. Becker



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

09:00

Genotype phenotype association in a large cohort of subjects with protein C or protein S deficiency

L. Böff (Frankfurt / Main, Germany)  
F. Bergmann (Hannover, Germany)  
A. Czwalinna (Hannover, Germany)  
C. Heller (Frankfurt / Main, Germany)  
M. Krause (Wiesbaden, Germany)  
W. Miesbach (Frankfurt / Main, Germany)  
S. Körber (Frankfurt / Main, Germany)  
E. Seifried (Frankfurt / Main, Germany)  
C. Geisen (Frankfurt / Main, Germany)

09:30

Plenary Session III, Room Montreal

Chairs:

A. Angelillo-Scherrer (Bern, Switzerland)  
B. Zieger (Freiburg, Germany)

09:30

Diagnosis and management of immune thrombocytopenia in childhood

T. Kühne (Basel, Switzerland)

10:00

How a protein becomes an autoantigen, lessons learned from HIT

A. Greinacher (Greifswald, Germany)

10:45

Special Symposium (Bayer), Room Delhi

Workshop Schmerz und Hämophilie - Interdisziplinäre Falldiskussionen mit Experten

Chairs:

K. Holstein (Hamburg, Germany)

Unter der Mitwirkung der aufgelisteten Referenten werden Fälle aus der Praxis und die verschiedenen Behandlungsoptionen diskutiert.

M. Bernateck (Hanover, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

10:45

## NEW, HOT or DISCUSSED I, Room Montreal

### Hemophilia

Chairs:

**C. Ecuriola-Ettingshausen** (Mörfelden-Walldorf, Germany)

**K. Kentouche** (Jena, Germany)

10:45

## Many new factor concentrates – what to know and consider before switching

C. Male (Vienna, Austria)

11:10

## New FVIII and FIX products – laboratory requirements

B. Pötzsch (Bonn, Germany)

11:35

## Possibilities to rebalance hemostasis in hemophilia

A. Angelillo-Scherrer (Bern, Switzerland)

10:45

## NEW, HOT or DISCUSSED II, Room Singapore

### Venous Thrombosis: Diagnosis and Treatment Issues

Chairs:

**B. Kemkes-Matthes** (Giessen, Germany)

**H. ten Cate** (Maastricht, The Netherlands)

10:45

## Rivaroxaban or fondaparinux for superficial-vein thrombosis - a randomized controlled non-inferiority trial

J. Beyer-Westendorf (Dresden, Germany / London, UK)

S. Schellong (Dresden, Germany)

H. Gerlach (Mannheim, Germany)

E. Rabe (Bonn, Germany)

J. Weitz (Hamilton, Ontario, Canada)

K. Jerseemann (Dresden, Germany)

K. Sahin (Cologne, Germany)

R. Bauersachs (Darmstadt, Germany / Mainz, Germany)

11:00

## Thrombophilia screening - Which patients, when, and what is appropriate

E. Lindhoff-Last (Frankfurt am Main, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:30

How to reverse anticoagulation - options for vitamin K antagonists and DOACs  
S. Eichinger-Hasenauer (Vienna, Austria)

11:00

Highlight Session IV, Room Boston 1+2  
Pediatric and Women Issues

Chairs:

**W. Eberl** (Braunschweig, Germany)

**U. Scholz** (Leipzig, Germany)

11:20

Clinical Pearl  
M. Albisetti Pedroni (Zurich, Switzerland)

11:35

The staphylococcal toxin Panton-Valentine Leukocidin induces neutrophil extracellular trap (NET) formation that leads to platelet activation.

M. F. Brodde (Muenster, Germany)

A. Bertling (Muenster, Germany)

S. Niemann (Muenster, Germany)

A. C. Fender (Duesseldorf, Germany)

H. Van de Vyver (Muenster, Germany)

B. Schlott (Jena, Germany)

C. Heilmann (Muenster, Germany)

G. Peters (Muenster, Germany)

B. Löffler (Jena, Germany)

B. E. Kehrel (Muenster, Germany)

11:47

Prothrombin fragment F1+2 in pregnancy is associated with thrombophilic risk factors and a history of venous thromboembolism (VTE)

R. B. Zotz (Duesseldorf, Germany)

R. E. Scharf (Duesseldorf, Germany)

A. Gerhardt (Ulm, Germany / Duesseldorf, Germany)

11:00

Best Poster, Room Shanghai 1+2  
Clinical Science

Chairs:

**F. Langer** (Hamburg, Germany)

**M. Nagler** (Bern, Switzerland)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:00

## Development and evaluation of a novel FVIII domain-specific immunoassay for characterization of anti-FVIII antibodies

B. Pezeshkpoor (Bonn, Germany)  
A.-C. Berkemeier (Bonn, Germany)  
J. Müller (Bonn, Germany)  
T. Albert (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)

11:06

## Blood clotting supports glioma invasion and colonization

J. Pilch (Homburg, Germany)  
A. Burkardt (Homburg, Germany)  
C. Wolter (Homburg, Germany)  
S. Urbschat (Homburg, Germany)  
R. Ketter (Homburg, Germany)  
D. Lessig (Homburg, Germany)  
I. Müller (Homburg, Germany)  
H. Eichler (Homburg, Germany)  
L. M. Knowles (Homburg, Germany)

11:12

## rVIII-SingleChain: Results of a Phase III PK, efficacy and safety study in children less than 12 years of age with severe hemophilia A

I. Pabinger (Vienna, Austria)  
O. Stasyshyn (Lviv, Ukraine)  
G. Iosava (Tbilisi, Georgia)  
C. Djambas Khayat (Beirut, Lebanon)  
J. Ong (Davao, Philippines)  
K. Fischer (Utrecht, Netherlands)  
F. Abdul Karim (Jalan Tun Razak, Kuala Lumpur, Malaysia)  
A. Veldman (Marburg, Germany)  
K. St. Ledger (King of Prussia, PA, United States)

11:18

## Comparison of biomarkers and immunological parameters between hemophilia patients, rheumatoid arthritis patients, and control subjects

R. Toenges (Frankfurt am Main, Germany)  
A. Wittenbrinck (Frankfurt am Main, Germany)  
S. Gundermann (Frankfurt am Main, Germany)  
M. Wahle (Augsburg, Germany)  
R. Schäfer (Frankfurt am Main, Germany)  
W. Miesbach (Frankfurt am Main, Germany)

11:24

## Activation and Inactivation of rVIII-SingleChain

C. Horn (Marburg, Germany)  
H. J. Metzner (Marburg, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:30

**Molecular genetic investigations and demonstration of founder effect in Osler-Rendu-Weber disease**

R. Gindele (Debrecen, Hungary)  
T. Major (Eger, Hungary)  
Z. Szabo (Debrecen, Hungary)  
K. B. Kovács (Debrecen, Hungary)  
G. Pfliegler (Debrecen, Hungary)  
Z. Bereczky (Debrecen, Hungary)

11:36

**The special role of anti-ADAMTS13-IgA in acquired TTP: Production induced by infectious microorganisms?**

I. Scharrer (Mainz, Germany)  
J. Falk (Mainz, Germany)

11:42

**Variable linkage with platelet functions of genetic mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficiencies**

M. Nagy (Maastricht, The Netherlands)  
T. G. Mastenbroek (Maastricht, The Netherlands)  
N. J. A. Mattheij (Maastricht, The Netherlands)  
S. de Witt (Maastricht, The Netherlands)  
K. J. Clemetson (Bern, Switzerland)  
J. Kirschner (Freiburg, Germany)  
A. S. Schulz (Ulm, Germany)  
J. M. E. M. Cosemans (Maastricht, The Netherlands)  
B. Zieger (Freiburg, Germany)  
J. W. M. Heemskerk (Maastricht, The Netherlands)

11:48

**Development and application of methods for the selective measurement of the human single amino acid exchange variant factor IX Padua**

A. Weber (Vienna, Austria)  
A. Engelmaier (Vienna, Austria)  
D. Voelkel (Orth, Austria)  
R. Pachlinger (Orth, Austria)  
F. Scheiflinger (Vienna, Austria)  
H. Rottensteiner (Vienna, Austria)

11:54

**Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII product**

A. Weber (Vienna, Austria)  
S. Haindl (Vienna, Austria)  
G. Mohr (Vienna, Austria)  
A. Engelmaier (Vienna, Austria)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:00

## Highlight Session V, Room Sydney

### Platelets

Chairs:

**L. Alberio** (Lausanne, Switzerland)

**C. Mannhalter** (Vienna, Austria)

11:00

### Highlight: Platelet granules - secretory and secretive

K. Jurk (Mainz, Germany)

11:20

### Clinical Pearl: Inherited thrombocytopenia due to ANKRD26 mutation

J. Rufener (Bern, Switzerland)

11:35

### Phospholipase D1 is a regulator of inflammatory platelet-endothelial interactions under high shear conditions

M. Klier (Düsseldorf, Germany)

N. Gowert (Düsseldorf, Germany)

S. Jäckel (Mainz, Germany)

C. Reinhardt (Mainz, Germany)

M. Elvers (Düsseldorf, Germany)

11:47

### Heterogeneous regulation of platelet adhesive-receptor shedding in thrombus formation

C. C. F. M. J. Baaten (Maastricht, The Netherlands)

F. Swieringa (Maastricht, The Netherlands)

T. Misztal (Białystok, Poland)

T. G. Mastenbroek (Maastricht, The Netherlands)

M. A. H. Feijge (Maastricht, The Netherlands)

M. M. P. C. Donners (Maastricht, The Netherlands)

P. W. Collins (Cardiff, United Kingdom)

P. E. J. van der Meijden (Maastricht, The Netherlands)

J. W. M. Heemskerk (Maastricht, The Netherlands)

12:15

## Satellite Symposium Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH, Room Boston 1+2

Moderne Gerinnungshemmung - Was gehört dazu, was ist zu beachten?

Chairs:

**R. Bauersachs** (Darmstadt, Germany)

**V. Hach-Wunderle** (Frankfurt am Main, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

12:15

Wie setzt man die oralen Antikoagulanzen am besten ein?

C.-E. Dempfle (Mannheim-Lindenhof, Germany)

12:45

Antikoagulation und Schlaganfallprophylaxe

M. Moser (Freiburg, Germany)

13:15

Behandlung und Rezidivprophylaxe von VTE

R. Bauersachs (Darmstadt, Germany)

12:15

Satellite Symposium Aspen Germany GmbH, Room Delhi

HIT oder nicht HIT - das ist hier die Frage!

Chairs:

**A. Greinacher** (Greifswald, Germany)

12:15

Einführung und Begrüssung

A. Greinacher (Greifswald, Germany)

12:25

HIT - im Alltag relevant?

E. Lindhoff-Last (Frankfurt am Main, Germany)

12:45

HIT? HIT! Vom Verdacht zur Diagnose

T. Bakchoul (Tuebingen, Germany)

13:05

Therapieansätze beim HIT-Patienten

A. Greinacher (Greifswald, Germany)

13:25

Der HIT-Patient in der Praxis

J. H. Beer (Baden, Switzerland)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

12:15

## Satellite Symposium Shire - Baxalta Deutschland GmbH, Room Kairo 1+2

Neue Behandlungswege bei Hemmkörpern

Chairs:

**A. Tiede** (Hanover, Germany)

12:15

## Begrüßung und Einleitung

A. Tiede (Hanover, Germany)

12:25

## Die individualisierte Therapie bei erworbener Hemmkörper Hämophilie

P. Knöbl (Vienna, Austria)

12:55

## 40 Jahre FEIBA: Erfahrungen während der ITI

J. Oldenburg (Bonn, Germany)

13:20

## Bypassing Agenzien während der ITI: Interim Analyse der ObsITI Studie

C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)

12:15

## Satellite Symposium Bayer, Room Shanghai 1+2

Ein Jahr im Zeichen von Kovaltry®

Chairs:

**A. Huth-Kühne** (Heidelberg, Germany)

**R. Knöfler** (Dresden, Germany)

12:15

## Einführung

12:20

## Pharmakokinetik in der Hämophilie-Therapie

D. Garmann (Wuppertal, Germany)

12:40

## Faktor VIII im Labor - eine Frage des Assays

J. Müller (Bonn, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

13:00

Ein Jahr Kovaltry - Erfahrungen aus der klinischen Praxis mit pädiatrischen Patienten  
C. Bidlingmaier (Munich, Germany)

13:15

Ein Jahr Kovaltry - Erfahrungen aus der klinischen Praxis mit erwachsenen Patienten  
G. Goldmann (Bonn, Germany)

12:15

Satellite Symposium Alexion Pharma Germany GmbH, Room Shanghai 3+4  
Thrombosen unklarer Ätiologie - Herausforderungen im klinischen Alltag

Chairs:

**M. Spannagl** (Munich, Germany)

12:15

Umfelddiagnostik bei spontanen Thrombosen  
F. Langer (Hamburg, Germany)

12:45

Thrombosen bei hämatologischen Erkrankungen  
H. K. Al-Ali (Halle, Germany)

13:15

Fallbeispiel atypische Thrombosen bei PNH  
J. Chromik (Frankfurt am Main, Germany)

14:00

GTH General Assembly, Room Montreal

16:00

Plenary Session IV, Room Montreal

Chairs:

**K. Clemetson** (Bern, Switzerland)

**J. Oldenburg** (Bonn, Germany)

16:00

Therapeutic genome editing with engineered nucleases  
T. Cathomen (Freiburg, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

16:30

[Phenotypic disorder profiling and next generation sequencing in bleeding disorders](#)  
W. H. Ouwehand (Cambridge, United Kingdom)

17:15

**Poster, Foyer 2. OG**

Acquired problems and alterations of coagulation

[Blood clotting supports glioma invasion and colonization](#)

J. Pilch (Homburg, Germany)

A. Burkardt (Homburg, Germany)

C. Wolter (Homburg, Germany)

S. Urbschat (Homburg, Germany)

R. Ketter (Homburg, Germany)

D. Lessig (Homburg, Germany)

I. Müller (Homburg, Germany)

H. Eichler (Homburg, Germany)

L. M. Knowles (Homburg, Germany)

[Improved values regarding acquired von Willebrand syndrome in patients with HeartMate III compared to HeartMate II](#)

U. Geisen (Freiburg, Germany)

K. Brehm (Freiburg, Germany)

G. Trummer (Freiburg, Germany)

F. Beyersdorf (Freiburg, Germany)

M. Berchtold-Herz (Freiburg, Germany)

C. Heilmann (Freiburg, Germany)

J. Schelling (Freiburg, Germany)

A. Schlagenhaut (Graz, Austria)

B. Zieger (Freiburg, Germany)

[Reconstituted whole blood using fresh frozen plasma versus coagulation factor concentrates: an in vitro study](#)

G. E. Iapichino (Vienna, Austria / Milan, Italy)

M. Ponschab (Vienna, Austria / Linz, Austria)

C. J. Schlimp (Vienna, Austria / Edinburgh, United Kingdom)

S. Süssner (Linz, Austria)

J. Cadamuro (Salzburg, Austria)

H. Redl (Vienna, Austria)

H. Schöchl (Vienna, Austria / Salzburg, Austria)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Hemostatic potential of reconstituted whole blood using fresh frozen plasma versus increasing concentration of lyoplasma

G. E. Iapichino (Vienna, Austria / Milan, Italy)  
M. Ponschab (Vienna, Austria / Linz, Austria)  
C. J. Schlimp (Vienna, Austria / Edinburgh, United Kingdom)  
C. Gabriel (Linz, Austria)  
J. Cadamuro (Salzburg, Austria)  
H. Redl (Vienna, Austria)  
H. Schöchl (Vienna, Austria / Salzburg, Austria)

## Trend in Hospital Cases of Acquired Hemophilia A (AHA) 2010 - 2014 in Germany

S. Wahler (Hamburg, Germany)  
A. Tiede (Hannover, Germany)

## Procoagulant microparticles and nanoparticles from whole blood reconstituted with age-different blood components.

M. Ponschab (Vienna, Austria / Linz, Austria)  
C. J. Schlimp (Vienna, Austria / Edinburgh, United Kingdom)  
L. Wisgrill (Vienna, Austria)  
A. Spittler (Vienna, Austria)  
C. Gabriel (Linz, Austria)  
J. Zipperle (Vienna, Austria)  
G. E. Iapichino (Vienna, Austria / Milan, Italy)  
H. Redl (Vienna, Austria)  
H. Schöchl (Vienna, Austria / Salzburg, Austria)

## Longitudinal analyses of microparticle-associated tissue factor activity and venous thromboembolism (VTE) in cancer patients

E.-M. Reitter (Vienna, Austria)  
A. Kaider (Vienna, Austria)  
C. Ay (Vienna, Austria)  
J. Thaler (Vienna, Austria)  
C. Marosi (Vienna, Austria)  
I. Pabinger (Vienna, Austria)

## Thrombin formation capacity in patients with two different left-ventricular assist devices and after heart transplantation

A. Schlagenhauf (Graz, Austria)  
U. Geisen (Freiburg, Germany)  
K. Brehm (Freiburg, Germany)  
G. Trummer (Freiburg, Germany)  
F. Beyersdorf (Freiburg, Germany)  
M. Berchtold-Herz (Freiburg, Germany)  
B. Zieger (Freiburg, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Chronic disseminated intravascular coagulation in a patient with antiphospholipid antibodies and acquired protein S deficiency

C. Dicke (Hamburg, Germany)  
K. Holstein (Hamburg, Germany)  
M. Voigtländer (Hamburg, Germany)  
F. Stahl (Hamburg, Germany)  
U. Schnoor (Hamburg, Germany)  
C. Bokemeyer (Hamburg, Germany)  
F. Langer (Hamburg, Germany)

Successful inhibitor eradication with ofatumumab in a patient with acquired hemophilia A

R. Fischer (Giessen, Germany)  
M. Alrifai (Giessen, Germany)  
K. Heidinger (Giessen, Germany)  
B. Kemkes-Matthes (Giessen, Germany)

Is a too low plasminogen level in the plasma of kidney transplant recipients the reason of irreversible rejection reactions?

H. E. Karges (Marburg, Germany)

Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on chronic hemodialysis: results of the VIVALDI study

O. Königsbrügge (Vienna, Austria)  
E. Grilz (Vienna, Austria)  
I. Pabinger (Vienna, Austria)  
M. Säemann (Vienna, Austria)  
C. Ay (Vienna, Austria)

Dual mechanical assistance with veno-arterial extracorporeal membrane oxygenation and percutaneous continuous-flow device: double trouble for von Willebrand factor

A. Rauch  
F. Vincent  
E. Jeanpierre  
C. Caron  
A. Dupont  
N. Rousse  
A. Vincentelli  
E. Robin  
E. Van Belle  
J. Goudemand  
S. Susen



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Direct oral thrombin inhibitor dabigatran etexilate is able to control chronic disseminated intravascular coagulation: a case report

W. Korte (St. Gallen, Switzerland)

L. Graf (St. Gallen, Switzerland)

Management of epidural bleeding in a patient with acquired hemophilia A masked by phenprocoumon therapy

M. Alrifai (Giessen, Germany)

R. Fischer (Giessen, Germany)

K. Heidinger (Giessen, Germany)

B. Kemkes-Matthes (Giessen, Germany)

17:15

Poster, Foyer 2. OG

Antithrombotic treatment

Differential effects of novel anticoagulants: fXa versus fIIa inhibition on coagulation and inflammation

S. Nazir (Magdeburg, Germany)

K. Shahzad (Magdeburg, Germany)

I. Gadi (Magdeburg, Germany)

M. Al-Dabet (Magdeburg, Germany)

S. Kohli (Magdeburg, Germany)

S. Ranjan (Magdeburg, Germany)

F. Bock (Magdeburg, Germany / Nashville, United States)

B. Isermann (Magdeburg, Germany)

How to assess in vivo anticoagulant effect of Rivaroxaban

D. Bertaggia Calderara (Lausanne, Switzerland)

D. Kröll (Bern, Switzerland)

C. Gerschheimer (Lausanne, Switzerland)

N. Nicolas (Lausanne, Switzerland)

G. Stirnimann (Bern, Switzerland)

L. Alberio (Lausanne, Switzerland)

Single-center experience with thrombolysis in high- and intermediate-risk pulmonary embolism

N. Herr (Freiburg, Germany)

C. Bode (Freiburg, Germany)

T. Wengenmayer (Freiburg, Germany)

D. Duerschmied (Freiburg, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Real life efficacy and safety of edoxaban for stroke prevention in atrial fibrillation – Results of the prospective NOAC registry (NCT01588119)

L. Tittl

J. Hecker

L. Wunder

T. Schreier

A. Reitter

J. Beyer-Westendorf

Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians

N. Mumoli (Livorno, Italy)

S. Barco (Mainz, Germany)

M. Cei (Piacenza, Italy)

M. Giorgi-Pierfranceschi (Piacenza, Italy)

M. Campanini (Novara, Italy)

A. Fontanella (Napoli, Italy)

W. Ageno (Varese, Italy)

F. Dentali (Varese, Italy)

CONKO-011: Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients – a randomized phase III study

M. Sinn (Berlin, Germany)

A. Jühling (Berlin, Germany)

J. Heinz (Freiburg, Germany)

M. Hellmann (Köln, Germany)

R. U. Trappe (Bremen, Germany)

T. Südhoff (Passau, Germany)

B. Günther (Düsseldorf, Germany)

L. Wislocka (Berlin, Germany)

J. Striefler (Berlin, Germany)

U. Pelzer (Berlin, Germany)

H. Riess (Berlin, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Long-term clinical outcomes of patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists: A prospective, multicenter cohort study of elderly patients with venous thromboemb

M. Nagler (Bern, Switzerland)

A. Angelillo-Scherrer (Bern, Switzerland)

M. Mean (Bern, Switzerland)

A. Limacher (Bern, Switzerland)

C. Abbal (Lausanne, Switzerland)

M. Righini (Geneva, Switzerland)

H.-J. Beer (Baden, Switzerland)

J. Osterwalder (St. Gallen, Switzerland)

B. Frauchiger (Frauenfeld, Switzerland)

M. Aschwanden (Basel, Switzerland)

C. Matter (Zurich, Switzerland)

N. Kucher (Bern, Switzerland)

J. Cornuz (Lausanne, Switzerland)

M. Banyai (Lucerne, Switzerland)

M. Husmann (Zurich, Switzerland)

D. Staub (Basel, Switzerland)

L. Mazzolai (Lausanne, Switzerland)

O. Hugli (Lausanne, Switzerland)

N. Rodondi (Bern, Switzerland)

D. Aujesky (Bern, Switzerland)

Clinical observations on potential interactions of phenprocoumon, colchicine and rivaroxaban in a patient with compound homozygosity for FV Leiden and familial Mediterranean fever (FMF, M680

L. Graf (St. Gallen, Switzerland)

K. Jung (St. Gallen, Switzerland)

W. Korte (St. Gallen, Switzerland)

17:15

Poster, Foyer 2. OG

Arterial thrombosis

Activation of neutrophils - but not endothelial cells - is regulated by serotonin during myocardial reperfusion injury

M. Mauler (Freiburg, Germany)

F. Glatzki

N. Herr

C. Schoenichen

T. Witsch

D. Stallmann

C. Bode

I. Ahrens

I. Hilgendorf

D. Duerschmied



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Protein C and factor X activities from patients with ischemic stroke and type II diabetes mellitus.

O. Kravchenko

O. Savchuk

T. Tsarenko

L. Ostapchenko

Inhibition of coagulation factor Xa attenuates myocardial ischemia reperfusion injury in mice

J. J. Posma (Maastricht, Netherlands)

J. J. Posthuma (Maastricht, Netherlands)

R. Van Oerle (Maastricht, Netherlands)

H. Ten Cate (Maastricht, Netherlands)

H. H. Spronk (Maastricht, Netherlands)

Idiopathic catastrophic thrombosis with happy end - a case report

J. Heid

H. A. Katus

O. Müller

The molecular etiology and pathophysiology of platelet-mediated aspirin responsive erythromelalgia and microvascular thrombosis in JAK2, CALR and MPL mutated thrombocythemia

J. J. Michiels (Antwerp, Belgium / Rotterdam, The Netherlands)

Effect of alpha-2 plasmin inhibitor p.Arg6Trp polymorphism and antigen level on the risk of myocardial infarction in young patients

E. Katona (Debrecen, Hungary)

A. Orosz (Debrecen, Hungary)

Z. Mezei (Debrecen, Hungary)

L. Balogh (Debrecen, Hungary)

Z. Bereczky (Debrecen, Hungary)

I. Edes (Debrecen, Hungary)

L. Muszbek (Debrecen, Hungary)

17:15

Poster, Foyer 2. OG

Bleeding disorders, coagulation and fibrinolytic factors



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

[rVIII-SingleChain: results of a phase III PK, efficacy and safety study in children less than 12 years of age with severe hemophilia A](#)

I. Pabinger (Vienna, Austria)  
O. Stasyshyn (Lviv, Ukraine)  
G. Iosava (Tbilisi, Georgia)  
C. Djambas Khayat (Beirut, Lebanon)  
J. Ong (Davao, Philippines)  
K. Fischer (Utrecht, Netherlands)  
F. Abdul Karim (Kuala Lumpur, Malaysia)  
A. Veldman (Marburg, Germany)  
K. St. Ledger (King of Prussia, PA, United States)

[Comparison of biomarkers and immunological parameters between hemophilia patients, rheumatoid arthritis patients, and control subjects](#)

R. Toenges (Frankfurt am Main, Germany)  
A. Wittenbrinck (Frankfurt am Main, Germany)  
S. Gundermann (Frankfurt am Main, Germany)  
M. Wahle (Augsburg, Germany)  
R. Schäfer (Frankfurt am Main, Germany)  
W. Miesbach (Frankfurt am Main, Germany)

[Introduction of a guideline for the treatment of synovitis in patients with hemophilia](#)

B. Habermann (Mainz, Germany)  
A. Seuser (Bonn, Germany)  
T. Hilberg (Wuppertal, Germany)

[The coagulation Factor XIII \(FXIII\) A subunit activation peptide directs the evolution of FXIIIA as a proteolytically activated dimeric molecule](#)

A. Biswas (Bonn, Germany)  
S. Singh (Bonn, Germany)  
V. Ivaskevicius (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)

[FSAP and altered fibrin clot structure: Is there a link to FXIII?](#)

M. Etscheid (Langen, Germany)  
N. Beer (Langen, Germany)  
R. Seitz (Langen, Germany)  
J. Dodt (Langen, Germany)

[Amidolytic thrombin activity under the ischemic stroke peptide pool influence](#)

T. Katrii  
O. Savchuk



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

What hemophilia patients expect from the new extended half-life (EHL) products and their willingness to switch - Results from the DACH region

S. von Mackensen (Hamburg, Germany)  
W. Kalnins (Hamburg, Germany)  
L. Hostettler (Altstätten, Switzerland)  
J. Krucker (Altstätten, Switzerland)  
M. Albisetti (Zurich, Switzerland)  
J. Weiss (Vienna, Austria)  
I. Pabinger (Vienna, Austria)  
J. Oldenburg (Bonn, Germany)

Monitoring of perioperative factor VIII treatment in a remote hospital by electronic diary smart medication<sup>TM</sup>

W. Mondorf (Frankfurt am Main, Deutschland)  
D. Schmoldt (Frankfurt am Main, Deutschland)

An Asp94Gly missense mutation in GP1BB causes severe Bernard-Soulier syndrome in an Iraqi family

D. Boeckelmann (Freiburg, Germany)  
E. Lerner (Freiburg, Germany)  
J. Schelling (Freiburg, Germany)  
K. Neubauer (Freiburg, Germany)  
K. Sandrock-Lang (Freiburg, Germany)  
B. Zieger (Freiburg, Germany)

Impact of maintaining higher FVIII trough levels with BAX 855: Rationale and design of the PROPEL study

H.-Y. Lee (Zurich, Switzerland)  
B. E. Abbuehl (Vienna, Austria)  
A. Hafeman (Westlake Village, CA, United States)  
W. Engl (Vienna, Austria)  
L. Patrone (Westlake Village, CA, United States)  
L. A. Valentino (Chicago, IL, United States)  
B. M. Ewenstein (Cambridge, MA, United States)

Nonacog beta pegol in adult and paediatric patients: pooled data from the paradigm<sup>TM</sup> clinical programme

J. Oldenburg (Bonn, Germany)  
M. Carcao (Toronto, Canada)  
S. R. Lentz (Iowa, United States)  
J. Mahlangu (Johannesburg, South Africa)  
M. Mancuso (Milan, Italy)  
T. Matshushita (Nagoya, Japan)  
C. Négrier (Lyon, France)  
W. H. Ong Clausen (Søborg, Denmark)  
S. Ehrenforth (Søborg, Denmark)  
G. Young (Los Angeles, United States)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Challenges in immune tolerance induction in an adult patient with non-severe hemophilia A.

P. Kuta (Erlangen, Germany)  
S. Achenbach (Erlangen, Germany)  
T. Zöller (Coburg, Germany)  
R. Zimmermann (Erlangen, Germany)

## Prevalence of overweight and obesity in children, adolescents and young adults with severe hemophilia A – results of 3 German pediatric hemophilia treatment centers

M. Olivieri (Munich, Germany)  
C. Königs (Frankfurt, Germany)  
S. Horneff (Bonn, Germany)  
C. Bidlingmaier (Munich, Germany)

## Pharmacokinetic results of two studies with a novel fibrinogen concentrate in subjects with afibrinogenaemia.

W. Stevens (Les Ulis, France)  
A. Bellon (Les Ulis, France)  
F. Bridey (Les Ulis, France)  
Ph. de Moerloose (Geneva, Switzerland)

## Pitfalls in carrier testing of haemophilia A

B. Preisler (Bonn, Germany)  
I. Radermacher (Bonn, Germany)  
I. Schwarze (Bonn, Germany)  
R. Kuhlemann (Bonn, Germany)  
R. Maurer (Bonn, Germany)  
J. Beckedahl (Bonn, Germany)  
L. Rothbrust (Bonn, Germany)  
J. Junen (Bonn, Germany)  
U. Scholz (Leipzig, Germany)  
B. Pezeshkpoor (Bonn, Germany)  
A. Pavlova (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)

## Long-term use of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B

S. Halimeh (Duisberg, Germany)  
A. Lubetsky (Tel Hashomer, Israel)  
U. Martinowitz (Tel Hashomer, Israel)  
T. Lissitchkov (Sofia, Bulgaria)  
A. Veldman (Marburg, Germany)  
E. Santagostino (Milan, Italy)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Resolution of target joints during once-weekly prophylaxis with rIX-FP in patients with hemophilia B

H. J. Laws (Dusseldorf, Germany)  
H. Hanabusa (Tokyo, Japan)  
C. Négrier (Lyon, France)  
T. Lissitchkov (Sofia, Bulgaria)  
G. Castaman (Vicenza, Italy / Florence, Italy)  
A. Tagliaferri (Parma, Italy)  
K. Fukutake (Tokyo, Japan)  
M. F. López Fernández (La Coruna, Spain)  
A. Veldman (Marburg, Germany, 10Milan, Italy)  
E. Santagostino

## Epidemiological insights about hemophilia B by analysis of German hospital quality reports

S. Wahler (Hamburg, Germany)  
A. Müller (München, Germany)

## Efficacy and safety of a VWF/FVIII concentrate in surgical procedures – results from the ongoing study Wilate-STATE

S. Halimeh (Duisburg, Germany)  
M. Daoud (Duisburg, Germany)  
M. Rieke (Hohne, Germany)  
T. Lang (Hohne, Germany)  
J. Kadar (Cologne, Germany)  
S. Alesci (Bad Homburg, Germany)  
J. Koscielny (Berlin, Germany)  
J. Feddern (Langenfeld, Germany)  
S. Seeger (Langenfeld, Germany)

## Combined congenital deficiency of coagulation factors VII and X in two siblings with heterozygous factor V Leiden mutation (R506Q)

K. Heidinger (Gießen, Germany)  
R. Fischer (Gießen, Germany)  
M. Alrifai (Gießen, Germany)  
A. Pavlova (Bonn, Germany)  
B. Kemkes-Matthes (Gießen, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Efficacy and safety of rVIII-SingleChain in 21 major surgeries

J. Oldenburg (Bonn, Germany)  
C. Djambas Khayat (Beirut, Lebanon)  
J. Mahlangu (Johannesburg, South Africa)  
R. Baker (Nedlands, Australia)  
C. Leissinger (New Orleans, United States)  
E. Santagostino (Milan, Italy)  
M. F. Lopez-Fernandez (La Coruña, Spain)  
F. Abdul Karim (Jalan Tun Razak, Kuala Lumpur, Malaysia)  
A. Veldman (Marburg, Germany, 10King of Prussia, United States, 11Vienna, Austria)  
K. St. Ledger  
I. Pabinger

## A preliminary study to find novel interaction partners for the coagulation factor XIII (FXIII) B subunit free form

S. Singh (Bonn, Germany)  
J. Dodt (Langen, Germany)  
A. Reuter (Langen, Germany)  
V. Ivaskevicius (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)  
A. Biswas (Bonn, Germany)

## Determining the causality of heterozygous missense mutations detected in F13A1 and F13B genes and reported from patients with mild coagulation factor XIII (FXIII) deficiency

A. Biswas (Bonn, Germany)  
A. Thomas (Bonn, Germany)  
J. Dodt (Langen, Germany)  
H. Philippou (Leeds, UK)  
E. Heathershaw (Leeds, UK)  
H. E. Jürgen (Bonn, Germany)  
V. Ivaskevicius (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)

## Annual Bleeding vs. factor VIII/IX consumption – comparison of result in 2014 and 2015 according to electronic diary smart-medication<sup>TM</sup>

R. Fischer (Giessen, Deutschland)  
H. Eichler (Homburg/Saar, Deutschland)  
K. Holstein (Hamburg, Deutschland)  
R. Klamroth (Berlin, Deutschland)  
A. Nimtz-Talaska (Frankfurt an der Oder, Deutschland)  
H. Richter (Münster Westfalen, Deutschland)  
K. Severin (Köln, Deutschland)  
C. Wermes (Hannover, Deutschland)  
W. Mondorf (Frankfurt am Main, Deutschland)



## The regulatory profile of the 5' untranslated region of F13A1 gene of coagulation factor XIII (FXIII) A subunit

M. A. Jamil (Bonn, Germany)  
S. Singh (Bonn, Germany)  
V. Ivaskevicius (Bonn, Germany)  
O. El-Maarri (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)  
A. Biswas (Bonn, Germany)

## Long-term immunogenicity, safety and efficacy of human-cl rhFVIII in previously treated children with severe hemophilia A

J. Bichler (Lachen, Switzerland)  
A. Klukowska (Warsaw, Poland)  
V. Vdovin (Moscow, Russian Federation)  
T. Szczepanski (Katowice, Poland)  
I. Dzhunova (Lachen, Switzerland)  
R. Liesner (London, United Kingdom)

## Individualized prophylaxis with Nuwiq® (Human-cl rhFVIII) in adult PTPs with severe hemophilia A

J. Bichler (Lachen, Switzerland)  
C. Kessler (Washington DC, USA)  
K. Meijer (Groningen, The Netherlands)  
A. Armstrong (Helsinki, Finland)  
S. Knaub (Lachen, Switzerland)  
G. Pezeshki (Hoboken, NJ, USA)  
M. Wang (Aurora, CO, USA)

## Efficacy and safety of Nuwiq® in clinical trials with previously treated patients with severe hemophilia A

R. Klamroth (Berlin, Germany)  
J. Bichler (Lachen, Switzerland)  
M. Jansen (Vienna, Austria)  
L. Belyanskaya (Lachen, Switzerland)  
S. Knaub (Lachen, Switzerland)  
R. Liesner (London, United Kingdom)  
J. Oldenburg (Bonn, Germany)  
A. Tiede (Hannover, Germany)  
C. Kessler (Washington DC, USA)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Interim bleeding data of 522 hemophilia A patients from the international AHEAD Study after 3 years of observation

K. Steinitz-Trost (Vienna, Austria)  
J. Oldenburg (Bonn, Germany)  
D. A. Tsakiris (Basel, Switzerland)  
C. Hermans (Brussels, Belgium)  
K. Khair (London, United Kingdom)  
R. Liesner (London, United Kingdom)  
M. G. Mazzucconi (Rome, Italy)  
G. Spotts (Westlake Village, USA)  
A. J. Reininger (Vienna, Austria)  
A. Gringeri (Vienna, Austria)

Feiba global outcome study (FEIBA-GO): first demographic data from a real world study on FEIBA in patients with inhibitors

K. Steinitz-Trost (Vienna, Austria)  
C. Escuriola Ettingshausen (Frankfurt-Moerfelden, Germany)  
C. Hermans (Brussels, Belgium)  
P. A. Holme (Oslo, Norway)  
C. Negrier (Bron, France)  
S. Rangarajan (Basingstoke, United Kingdom)  
A. Rocino (Naples, Italy)  
J. Windyga (Warsaw, Poland)  
A. Gringeri (Vienna, Austria)  
R. Crea (Vienna, Austria)  
A. R. Cid (Valencia, Spain)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

[Inhibitor development in previously untreated patients with severe hemophilia A treated with human-cl rhFVIII, a new generation recombinant FVIII of human origin](#)

A. Russo (Mainz, Germany)  
C. Altisent (Barcelona, Spain)  
A. Borel-Derlon (Caen, France)  
H. Chambost (Marseille, France)  
M. Gattens (Cambridge, United Kingdom)  
Y. Gruel (Tours, France)  
A. Klukowska (Warsaw, Poland)  
C. Koenigs (Frankfurt 618 elden-Walldorf, Germany ck1, S. Gundermann<sup>1</sup>, M. Wahle<sup>2</sup>, R. Schäfer<sup>1</sup>, W. Miesbach<sup>1</sup>)  
S. Lohr  
R. J. Liesner  
M. Sigaud  
M. Abashidze  
O. Aleinkova  
M. J. Belletrutti  
M. Carcao  
A. K. C. Chan  
L. Dubey  
J. Ducore  
N. A. Fouzia  
N. Kavardakova  
M. El Khorassani  
S. Lohade  
V. Turea  
J. K. M. Wu  
V. Vdovin

[Autologous serum infusion induces no thrombin formation but generation of activated protein C](#)

C. Berens (Bonn, Germany)  
H. Rühl (Bonn, Germany)  
J. Rossa (Bonn, Germany)  
A. Winterhagen (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)  
J. Müller (Bonn, Germany)  
B. Pötzsch (Bonn, Germany)

[Treatment of acquired hemophilia A with recombinant porcine FVIII in Germany](#)

C. Hart (Regensburg, Germany)  
A. Huth-Kühne (Heidelberg, Germany)  
R. Klamroth (Berlin, Germany)  
M. Angstwurm (München, Germany)  
M. Stemberger (München, Germany)  
M. Spannagl (München, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

**Pulmonary embolism in a patient with severe factor VII deficiency after femoral neck fracture despite thromboprophylaxis with low-molecular-weight heparin**

K. Holstein (Hamburg, Germany)

M. Voigtländer (Hamburg, Germany)

C. Dicke (Hamburg, Germany)

F. Langer (Hamburg, Germany)

**Genetic therapy for hemophilia: What's new?**

M.-K. Holz (Essen, Germany)

K. Waack-Buchholz (Essen, Germany)

D. Reinhardt (Essen, Germany)

H. Hanenberg (Düsseldorf, Germany)

**In-vitro analysis of siRNA based inhibition of function of activated protein C (APC): Towards an alternative therapeutic option for hemophilia.**

D. Mirgal (Mumbai, Maharashtra)

V. Pujari (Mumbai, Maharashtra)

K. Ghosh (Surat, Gujrat, India)

S. Shetty (Mumbai, Maharashtra)

**Novel insights in the molecular etiology of recessive von Willebrand disease 2N due to D'D3 Factor VIII-binding site mutations of von Willebrand factor**

J. J. Michiels (Edegem, Belgium / Rotterdam, Netherlands)

F. Hansen (London, United Kingdom)

R. Dingle (London, United Kingdom)

A. Batorova (Bratislava, Slovakia)

T. Prigancova (Bratislava, Slovakia)

P. Smejkal (Brno, Czech Republic)

M. Penka (Brno, Czech Republic)

I. Vangenechten (Edegem, Belgium)

A. Gadisseur (Edegem, Belgium)

**Protein S and purpura fulminans: What's new?**

R. Prince (Bern, Switzerland)

S. Calzavarini (Bern, Switzerland)

M. Yasuhiro (Chiba, Japan)

J. H. Griffin (La Jolla, USA)

J. A. Fernández (La Jolla, USA)

F. Saller (Le Kremlin-Bicetre, France)

A. Angelillo-Scherrer (Bern, Switzerland)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Successful factor VIII re-exposure after long-term aPCC prophylaxis in two hemophilia A patients with inhibitors

C. Königs (Frankfurt, Germany)  
A. Siegemund (Leipzig, Germany)  
D. Stichel (Frankfurt, Germany)  
A. Orlowski (Frankfurt, Germany)  
C. Heller (Frankfurt, Germany)  
J. Kahle (Frankfurt, Germany)  
D. Schwabe (Frankfurt, Germany)  
U. Scholz (Leipzig, Germany)

## rVIII-SingleChain in hemophilia A patients: A population pharmacokinetic model

Y. Zhang (King of Prussia, United States)  
J. Roberts (King of Prussia, United States)  
D. Bensen-Kennedy (King of Prussia, United States)  
A. Veldman (Marburg, Germany)  
K. S. Ledger (King of Prussia, United States)  
J. Sidhu (Parkville, Australia)

## Comparison of data security of the electronic patient diary smart medication <sup>TM</sup> with manual documentation in a paper diary

A. Roesch (Dreieich, Germany)  
R. Fischer (Giessen, Germany)  
W. Mondorf (Frankfurt am Main, Germany)  
D. Schmoldt (Dreieich, Germany)

17:15

## Poster, Foyer 2. OG

### Laboratory tests

## Development and evaluation of a novel FVIII domain-specific immunoassay for characterization of anti-FVIII antibodies

B. Pezeshkpoor (Bonn, Germany)  
A.-C. Berkemeier (Bonn, Germany)  
J. Müller (Bonn, Germany)  
T. Albert (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)

## Activation and inactivation of rVIII-SingleChain

C. Horn (Marburg, Germany)  
H. J. Metzner (Marburg, Germany)



## Protein Z - Does its analyzation make any clinical sense?

G. Kappert (Duisburg, Deutschland)  
M. Daoud (Duisburg, Deutschland)  
M. Siebert (Duisburg, Deutschland)  
H. Rott (Duisburg, Deutschland)  
S. Halimeh (Duisburg, Deutschland)

## Platelet aggregation testing on a routine coagulation analyzer

W. Miesbach (Frankfurt, Germany)  
B. Zwinge (Frankfurt, Germany)  
R. Toenges (Frankfurt, Germany)  
L. Karmal (Frankfurt, Germany)  
V. Makki (Frankfurt, Germany)  
S. Müller (Frankfurt, Germany)  
S. Gundermann (Frankfurt, Germany)

## Unambiguous and sensitive measurement of active coagulation proteases

A. Weber (Vienna, Austria)  
A. Engelmaier (Vienna, Austria)  
G. Prodingner (Vienna, Austria)

## Quantification of TAFI in human plasma by LC-MS/MS

M. Rauh (Erlangen, Germany)  
S. Weiß (Erlangen, Germany)  
K. Heußner (Erlangen, Germany)  
M. Chada (Erlangen, Germany)  
J. Zierk (Erlangen, Germany)  
W. Rascher (Erlangen, Germany)  
H.-G. Topf (Erlangen, Germany)

## Diagnostic challenges of von Willebrand disease

S. Schneppenheim (Hamburg, Germany)  
R. Dittmer (Hamburg, Germany)  
H. El-Abd Müller (Hamburg, Germany)  
U. Budde (Hamburg, Germany)

## A rapid and simple assay for the determination of ADAMTS-13 activity

M. Griffiths (Vienna, Austria)  
H. Vetr (Vienna, Austria)  
N. B. Binder (Vienna, Austria)



Evaluation and clinical validation of a chromogenic FIX assay for reliable post infusion measurements of recombinant and next generation factor IX products

J. Müller (Bonn, Germany)

J. Oldenburg (Bonn, Germany)

B. Pötzsch (Bonn, Germany)

TechnoZym® ADAMTS-13 activity assay for determination of inhibitory antibodies against ADAMTS-13

L. Wagner (Vienna, Austria)

F. Nasufi (Vienna, Austria)

M. Kafka (Vienna, Austria)

N. B. Binder (Vienna, Austria)

Measuring direct oral anticoagulants in standardized fully automated thrombin generation on Ceveron® alpha

L. Wagner (Vienna, Austria)

E. Wimmer (Wels, Austria)

J. Seier (Wels, Austria)

N. B. Binder (Vienna, Austria)

A. C. Haushofer (Wels, Austria)

Evaluation of DOAC Interferences on Technoclot® PT Owren

L. Rosenmayr (Vienna, Austria)

L. Wagner (Vienna, Austria)

N. B. Binder (Vienna, Austria)

Difficulties in diagnosing antiphospholipid syndrome in patients undergoing DOAC therapy

T. Flieder (Bad Oeynhausen, Germany)

M. Weiser (Bad Oeynhausen, Germany)

T. Eller (Bad Salzuflen, Germany)

M. Dittrich (Würzburg, Germany)

K. von Barga (Bad Oeynhausen, Germany)

F. Knüttgen (Bad Oeynhausen, Germany)

A. Hohbein (Bad Oeynhausen, Germany)

J. Kuhn (Bad Oeynhausen, Germany)

C. Knabbe (Bad Oeynhausen, Germany)

I. Birschmann (Bad Oeynhausen, Germany)

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in the one-stage assay

A. Veldman (Marburg, Germany)

A. Feussner (Marburg, Germany)

U. Kalina (Marburg, Germany)

K. St. Ledger (King of Prussia, PA, USA)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII product

A. Weber (Vienna, Austria)  
S. Haindl (Vienna, Austria)  
G. Mohr (Vienna, Austria)  
A. Engelmaier (Vienna, Austria)

rVIII-SingleChain plasma activity can be measured using both the one-stage and the chromogenic substrate assay: Results from an international field study

A. Veldman (Marburg, Germany)  
A. Feussner (Marburg, Germany)  
U. Kalina (Marburg, Germany)  
H. Metzner (Marburg, Germany)  
C. Horn (Marburg, Germany)  
A. Stowers (Marburg, Germany)  
K. St. Ledger (King of Prussia, PA, United States)

Platelet-dependent von Willebrand factor activity - an important constituent of the diagnostic repository to classify von Willebrand syndrome.

O. Tiebel (Dresden, Germany)  
K. Trautmann (Dresden, Germany)  
U. Platzbecker (Dresden, Germany)  
R. Knöfler (Dresden, Germany)  
G. Siegert (Dresden, Germany)

Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: comparison of diagnostic accuracy, reproducibility, and costs in clinical practice

A. Bankova (Lucerne, Switzerland)  
Y. Andres (Muri, Switzerland)  
M. Horn (Bern, Switzerland)  
L. Alberio (Lausanne, Switzerland)  
M. Nagler (Bern, Switzerland)

Is platelet aggregation testing dependent on fibrinogen level?

L. Graf (St. Gallen, Switzerland)  
J. Worden (St. Gallen, Switzerland)  
W. Korte (St. Gallen, Switzerland)

Replacing the aPTT for monitoring of unfractionated heparin with the Prothrombinase induced Clotting Time (PiCT) – significant influence on dosing.

W. Korte (St. Gallen, Switzerland)  
L. Graf (St. Gallen, Switzerland)  
C. Knöpfel (St. Gallen, Switzerland)



## Clauss fibrinogen assay obviously underestimates fibrinogen level not confirmed in thromboelastometry – A case report

T. Lang (Hohne, Germany)  
M. Rieke (Hohne, Germany)  
M. Bachler (Innsbruck, Austria)  
B. Schenk (Innsbruck, Austria)  
M. Hermann (Innsbruck, Austria)  
M. Tollnick (Hohne, Germany)  
D. Fries (Innsbruck, Austria)

## A Flow cytometer-based platelet aggregation assay permits platelet function testing in small blood volumes

S. Liedtke (Greifswald, Germany)  
J. Wesche (Greifswald, Germany)  
K. Althaus (Greifswald, Germany)  
T. Thiele (Greifswald, Germany)  
A. Greinacher (Greifswald, Germany)

## Genetic heterogeneity in patients with von Willebrand disease type I: a regional study from Northeast Germany

M. Steiner (Rostock, Germany)  
D. Jenzen (Rostock, Germany)  
R. Toenges (Rostock, Germany)  
D. Friday (Rostock, Germany)  
B. Krammer-Steiner (Rostock, Germany)

## Comparison of factor VIII assays using physiological triggers

G. J. Praefcke (Langen, Germany)  
M. Kusch (Langen, Germany)  
C. Grundmann (Langen, Germany)  
S. Keitel (Langen, Germany)  
A. Hunfeld (Langen, Germany)  
R. Seitz (Langen, Germany)

17:15

## Poster, Foyer 2. OG

Pediatric and neonatal thrombosis and hemostasis



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

The „German Pediatric Hemophilia Research Database“ (GEPHARD) – a project of the ‘Standing Committee Pediatrics of the Society for Thrombosis and Hemostasis Research’ to improve the quality

C. Bidlingmaier (Munich, Germany)  
C. Escuriola Ettingshausen (Mörfelden, Germany)  
K. Kentouche (Jena, Germany)  
M. Olivieri (Munich, Germany)  
W. Eberl (Braunschweig, Germany)  
B. Zieger (Freiburg, Germany)  
K. Kurnik (Munich, Germany)  
C. Königs (Frankfurt Main, Germany)  
for the GEPHARD Study Group

Acquired von Willebrand disease in infants with aortopulmonary shunt

G. Wiegand (Tuebingen, Germany)  
V. Icheva (Tuebingen, Germany)  
U. Budde (Hamburg, Germany)  
M. Hofbeck (Tuebingen, Germany)

Late onset of thrombosis in siblings with homozygous protein C deficiency

C. Wermes (Hannover, Germany)  
M. Suslovych (Hannover, Germany)  
C. Detering (Hannover, Germany)  
M. von Depka (Hannover, Germany)

Adolescent male suffering from thrombosis is not uncommon

I. Wieland (Hannover, Germany)  
A. Biering (Wolfsburg, Germany)  
K. W. Sykora (Hannover, Germany)

Thrombotic events in the neonatal period – a case series of common manifestations

M. Rohde (Giessen, Germany)  
V. Vaillant (Giessen, Germany)  
H. Ehrhardt (Giessen, Germany)  
K.-P. Zimmer (Giessen, Germany)  
B. Kemkes-Matthes (Giessen, Germany)  
C. Mauz-Körholz (Giessen, Germany)  
H. Hauch (Giessen, Germany)



## Anterior spinal artery syndrome in pediatric patients: diagnostic and therapy

A. M. Cseh (Freiburg, Germany)  
J. Kirschner (Freiburg, Germany)  
H. Meinicke (Freiburg, Germany)  
H. Fuchs (Freiburg, Germany)  
B. Zieger (Freiburg, Germany)

## Systemic mast cell activation disease during adolescence and heparin levels in blood plasma

M. Vysniauskaite\* (Bonn, Germany)  
A. Selbitz (Bonn, Germany)  
S. Unkrig (Bonn, Germany)  
F.-J. Dumoulin (Bonn, Germany)  
J. Homann (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)  
G. J. Molderings\* (Bonn, Germany)  
H.-J. Hertfelder\* (Bonn, Germany)  
\*equally contributing authors

17:15

## Poster, Foyer 2. OG

### Platelets - Physiology and Disorders of platelet number and function

## Annexin A7 (ANX7) regulates collagen-dependent platelet activation and Ca<sup>2+</sup> signaling

S. Geue (Tübingen, Germany)  
B. Walker-Allgaier (Tübingen, Germany)  
D. Eißler (Tübingen, Germany)  
P. Münzer (Tübingen, Germany)  
F. Lang (Tübingen, Germany)  
M. Gawaz (Tübingen, Germany)  
O. Borst (Tübingen, Germany)

## The special role of anti-ADAMTS13-IgA in acquired TTP: Production induced by infectious microorganisms?

J. Falk  
T. Vigh  
I. Scharrer



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Variable linkage with platelet functions of genetic mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficiencies

M. Nagy (Maastricht, The Netherlands)  
T. G. Mastenbroek (Maastricht, The Netherlands)  
N. J. A. Mattheij (Maastricht, The Netherlands)  
S. de Witt (Maastricht, The Netherlands)  
K. J. Clemetson (Bern, Switzerland)  
J. Kirschner (Freiburg, Germany)  
A. S. Schulz (Ulm, Germany)  
J. M. E. M. Cosemans (Maastricht, The Netherlands)  
B. Zieger (Freiburg, Germany)  
J. W. M. Heemskerk (Maastricht, The Netherlands)

Phosphorylation of the protein phosphatase 2A inhibitor alpha-endosulfine (ENSA) at two distinct sites, serine 67 and serine 109, in human platelets

E. Walter (Mainz, Germany)  
O. Pagel (Dortmund, Germany)  
R. Zahedi (Dortmund, Germany)  
A. Smolenski (Dublin, Ireland)  
S. Gambaryan (Mainz, Germany / St. Petersburg, Russia)  
U. Walter (Mainz, Germany)  
K. Jurk (Mainz, Germany)

Immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies in a cohort of 47 patients with acquired thrombotic thrombocytopenic purpura

G. Sinkovits (Budapest, Hungary)  
M. Réti (Budapest, Hungary)  
Z. Prohászka (Budapest, Hungary)

Intra- and intercellular fate of iron oxide nanoparticles in platelets

K. Aurich (Greifswald, Germany)  
J. Wesche (Greifswald, Germany)  
R. Koch (Greifswald, Germany)  
J. Fuhrmann (Greifswald, Germany)  
A. Greinacher (Greifswald, Germany)

Frequency and analysis of hospital cases of heparin induced thrombocytopenia type 2 (HIT 2) in Germany

S. Wahler (Hamburg, Germany)  
A. Müller (München, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Phenotyping platelets from patients with inherited platelet disorders by immunofluorescence microscopy

K. Althaus (Greifswald, Germany)  
C. Blumentritt (Greifswald, Germany)  
U. Strobel (Greifswald, Germany)  
T. Bakchoul (Tübingen, Germany)  
A. Greinacher (Greifswald, Germany)

## Initiation of a prospective observational cohort study of patients with acquired thrombotic thrombocytopenic purpura (TTP)

T. Falter (Mainz, Germany)  
A. Trinchero (Mainz, Germany)  
K. Jurk (Mainz, Germany)  
H. Roßmann (Mainz, Germany)  
K. Lackner (Mainz, Germany)  
B. Lämmle (Mainz, Germany / Bern, Switzerland)  
C. von Auer (Mainz, Germany)

## Evaluation of platelet parameters in pediatric thrombocytopenic patients

R. Knöfler (Dresden, Germany)  
S. Hackel (Dresden, Germany)  
B. Arneth (Dresden, Germany)  
J. Lohse (Dresden, Germany)  
J. Stächele (Dresden, Germany)  
O. Tiebel (Dresden, Germany)

## The power of large platelets: Comprehensive functional characterization of large and small platelets from healthy volunteers.

S. Handtke (Greifswald, Germany)  
R. Palankar (Greifswald, Germany)  
M. Ferrara (Greifswald, Germany)  
S. Cauhan (Greifswald, Germany)  
A. Greinacher (Greifswald, Germany)  
T. Thiele (Greifswald, Germany)

## Evaluation of platelet activation after electric cardioversion

J. Gaugler (Graz, Austria)  
A. Schlagenhaut (Graz, Austria)  
B. Egner (Graz, Austria)  
W. Schwinger (Graz, Austria)  
E. Bisping (Graz, Austria)  
S. Gallistl (Graz, Austria)  
H. Haidl (Graz, Austria)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Platelet dense granule production and dense granule release defects in pediatric patients with storage pool disorder

J. Eilenberger (Würzburg, Germany)  
G. Manukjan (Würzburg, Germany)  
O. Andres (Würzburg, Germany)  
C. Schambeck (Munich, Germany)  
S. Eber (Munich, Germany)  
H. Schulze (Würzburg, Germany)

Practical limitations of diagnostic algorithms in heparin induced thrombocytopenia: A case report.

S. Nowak-Harnau  
S. Enkel  
B. Zimmermann  
C. Reiss  
T. Bakchoul

Supra-normal closure time caused by recombinant von Willebrand factor in PFA

T. Kragh (Munich, Germany)  
M. Spannagl (Munich, Germany)

Prophylactic plasma treatment in patients with hereditary thrombotic thrombocytopenic purpura

Z. Cermakova (Ostrava, Czech Republic)  
P. Kovarova (Ostrava, Czech Republic)  
J. A. Kremer Hovinga (Bern, Switzerland)

17:15

Poster, Foyer 2. OG

Vascular wall biology and disorders

Molecular genetic investigations and demonstration of founder effect in Osler-Rendu-Weber disease

R. Gindele (Debrecen, Hungary)  
T. Major (Eger, Hungary)  
Z. Szabo (Debrecen, Hungary)  
K. B. Kovács (Debrecen, Hungary)  
G. Pfliegler (Debrecen, Hungary)  
Z. Bereczky (Debrecen, Hungary)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## CLIC1 supports mechanisms related to thrombosis and vascular repair

L. M. Knowles (Homburg, Germany)  
P. Niewald (Homburg, Germany)  
E. Ampofo (Homburg, Germany)  
A. Drawz (Homburg, Germany)  
I. Müller (Homburg, Germany)  
H. Eichler (Homburg, Germany)  
J. Pilch (Homburg, Germany)

## Collagen V alpha 2 as a direct target of miR-143 in arteriogenesis

T. Hammerschick (Giessen, Germany)  
K. Troidl (Bad Nauheim, Germany)  
K. T. Preissner (Giessen, Germany)  
S. Fischer (Giessen, Germany)

## Activated protein C protects against accelerated atherosclerosis in diabetes by restricting p66shc expression in macrophages

K. Shahzad (Magdeburg, Germany)  
I. Gadi (Magdeburg, Germany)  
S. Nazir (Magdeburg, Germany)  
M. Al-Dabet (Magdeburg, Germany)  
S. Kohli (Magdeburg, Germany)  
S. Ranjan (Magdeburg, Germany)  
F. Bock (Magdeburg, Germany / Nashville, United States)  
B. Isermann (Magdeburg, Germany)

## Autophagy status in factor VIII secreting endothelial cells

M. A. Jamil (Bonn, Germany)  
H. Singer (Bonn, Germany)  
N. Nüsken (Bonn, Germany)  
J. Oldenburg (Bonn, Germany)  
O. El-Maarri (Bonn, Germany)

## Analysis of proteolytic von Willebrand factor (VWF) fragments in patients with VWF-related diseases

J. Irle (Mainz, Germany)  
K. Schwierczek (Mainz, Germany)  
H. Rossmann (Mainz, Germany)  
T. Falter (Mainz, Germany)  
C. von Auer (Mainz, Germany)  
A. Trinchero (Mainz, Germany)  
K. Lackner (Mainz, Germany)  
Z. Ruggeri (La Jolla, CA, USA)  
B. Lämmle (Mainz, Germany)  
K. Jurk (Mainz, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

In patients with uncontrolled arterial hypertension platelets and coagulation factor XI are responsible of modifications of thrombin generation.

J. Lagrange (Mainz, Germany)  
Y. Weihert (Mainz, Germany)  
S. Kossmann (Mainz, Germany)  
T. Münzel (Mainz, Germany)  
S. Karbach (Mainz, Germany)  
P. Wenzel (Mainz, Germany)

Investigating the interconnection between complement and coagulation in xenotransplantation

R. Sfriso (Bern, Switzerland)  
N. Klymiuk (Munich, Germany)  
E. Wolf (Munich, Germany)  
J. Seebach (Geneva, Switzerland)  
R. Rieben (Bern, Switzerland)

Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension

S. Kossmann (Mainz, Germany)  
J. Lagrange (Mainz, Germany)  
S. Jackel (Mainz, Germany)  
K. Jurk (Mainz, Germany)  
M. Ehlken (Mainz, Germany)  
A. Daiber (Mainz, Germany)  
U. Walter (Mainz, Germany)  
T. Renné (Hamburg, Germany / Stockholm, Schweden)  
W. Ruf (Mainz, Germany / La Jolla, USA)  
T. Munzel (Mainz, Germany)  
P. Wenzel (Mainz, Germany)

17:15

Poster, Foyer 2. OG

Venous thrombosis

Clinical relevance of marginal low Protein S

P. Lodemann (Berlin, Germany)  
D. Peetz (Berlin, Germany)  
T. Held (Berlin, Germany)  
W. Ludwig (Berlin, Germany)  
J. Oldenburg (Bonn, Germany)



## Characterisation of previously unknown protein C gene variants

S. Körber (Frankfurt am Main, Germany)  
L. Böff (Frankfurt am Main, Germany)  
F. Bergmann (Hannover, Germany)  
A. Czwalinna (Hannover, Germany)  
B. Bomke (Düsseldorf, Germany)  
C. Heller (Frankfurt am Main, Germany)  
M. Krause (Wiesbaden, Germany)  
B. Luxembourg (Frankfurt am Main, Germany)  
K. Kurnik (Munich, Germany)  
W. Miesbach (Frankfurt am Main, Germany)  
C. Geisen (Frankfurt am Main, Germany)

## GE-CAT - German Evaluation of Cancer associated Thrombosis A prospective register trial for patients with hematological and oncological diseases and venous thromboembolism in Berlin

A. Jühling (Berlin, Germany)  
M. Sinn (Berlin, Germany)  
E. T. Wolter (Berlin, Germany)  
S. Bischoff (Berlin, Germany)  
U. Pelzer (Berlin, Germany)  
L. Wislocka (Berlin, Germany)  
J. K. Striefler (Berlin, Germany)  
F. Brandes (Berlin, Germany)  
H. Riess (Berlin, Germany)  
R. Klamroth (Berlin, Germany)

## Study of fibrinolytic parameters in Indian patients with venous thrombosis

A. Prabhudesai (Mumbai, India)  
S. Shetty (Mumbai, India)  
K. Ghosh (Surat, India)  
B. Kulkarni (Mumbai, India)

## Characterization of antithrombin variants in thrombotic patients with normal and reduced activity.

R. Deshpande (Mumbai, India)  
B. Kulkarni (Mumbai, India)  
K. Ghosh (Surat, India)  
S. Shetty (Mumbai, India)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Application of massive parallel sequencing searching for rare genetic variants associated with thrombophilia - implementation to clinical practice.

P. Vrtel

L. Slavik

R. Vodicka

R. Vrtel

J. Ulehlova

J. Prochazkova

A. Hlusi

M. Palova

M. Prochazka

Advances in diagnosis, classification and management of lower extremity deep vein thrombosis (DVT), prevention of DVT recurrence and the post-thrombotic syndrome: personal experiences and a

J. J. Michiels (Rijnmond Rotterdam, Netherlands / Rotterdam, Netherlands)

W. Moosdorff (Rijnmond Rotterdam, Netherlands)

J. M. Michiels (Rijnmond Rotterdam, Netherlands / Rotterdam-Zuid Rotterdam, Netherlands)

M. U. Lao (Rijnmond Rotterdam, Netherlands)

H. Maasland (Rijnmond Rotterdam, Netherlands)

H. Smeets (Rijnmond Rotterdam, Netherlands)

M. Han (Rijnmond Rotterdam, Netherlands)

P. Dulicek (Prague, Czech Republic)

V. Stvrtinova (Prague, Czech Republic / Bratislava, Slovakia)

Z. Pecsvarady (Prague, Czech Republic)

P. Poredos (Prague, Czech Republic / Ljubljana, Slovenia)

A. Gadisseur (Antwerp, Belgium)

W. Schroyens (Antwerp, Belgium)

The role of an endothelial specific g-protein coupled receptor in thrombosis

L. Gottlob (Stockholm, Sweden)

P. Dusart (Stockholm, Sweden)

L. Fagerberg (Solna, Sweden)

D. A. Trégouët (Paris, France)

P. Morange (Marseille, France)

M. Germain (Paris, France)

M. Civelek (Charlottesville, United States)

T. Renne (Stockholm, Sweden / Hamburg, Germany)

J. Odeberg (Stockholm, Sweden)

L. Butler (Stockholm, Sweden)

17:15

Poster, Foyer 2. OG

Women issues in thrombosis and hemostasis



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Angiogenesis in a porcine von Willebrand disease model

M. von Depka (Hannover, Germany)  
H. Allerkamp (Hannover, Germany)  
C. Pfarrer (Hannover, Germany)  
M. Ekhlas-Hundrieser (Hannover, Germany)  
C. Detering (Hannover, Germany)  
S. Lehner (Hannover, Germany)

## Successful pregnancy in patient with homozygous sickle cell disease and prior pulmonary embolism – a case report

J. Notter  
G. Amstad  
B. Drexler  
K. Loukidis

## Highly procoagulant extracellular vesicles in amniotic fluid

J. Thaler (Vienna, Austria)  
L. Hell (Vienna, Austria)  
L. Wisgrill (Vienna, Austria)  
C. Ay (Vienna, Austria)  
A. Spittler (Vienna, Austria)  
M. Schwameis (Vienna, Austria)  
B. Jilma (Vienna, Austria)  
P. Altevogt (Heidelberg, Germany)  
I. Pabinger (Vienna, Austria)

## Dead fetus syndrome (DFS) in 2017 - a no more existing entity ? From individual patients to pathophysiological insights

F. Bergmann (Hannover, Germany)  
A. Czwalinna (Hamburg, Germany)  
H. Groening (Hannover, Germany)  
R. Schwerdfeger (Hannover, Germany)  
R. Schild (Hannover, Germany)  
U. Budde (Hamburg, Germany)

## Risk of pregnancy-associated recurrent venous thromboembolism (VTE) in women with a history of first venous thrombosis

A. Gerhardt (Ulm, Germany / Duesseldorf, Germany)  
R. E. Scharf (Duesseldorf, Germany)  
R. B. Zotz (Duesseldorf, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Comparison of two laboratory methods for thrombin generation in pregnancy with high risk for thrombosis

M. Schwethelm (Basel, Switzerland)

M. Martinez (Basel, Switzerland)

I. Hoesli (Basel, Switzerland)

D. Tsakiris (Basel, Switzerland)

## Bernard Soulier syndrome in pregnancy and delivery – a case report

K. Liebscher (Leipzig, Germany)

I. Niemann (Leipzig, DE)

I. Bogner (Leipzig, DE)

A. Siegemund (Leipzig, DE)

M. Krause (Leipzig, DE)

U. Scholz (Leipzig, DE)

## Successful pregnancy outcome in a case of JAK2 positive essential thrombocytemia after treatment with peginterferon alpha-2b

M.-V. Teleanu (Ulm, Germany )

S. Jaramillo (Ulm, Germany )

S. Schönsteiner (Ulm, Germany)

S. Estenfelder (Ulm , Germany)

P. Schwarzwälder (Ulm, Germany)

C. Langer (Ulm, Germany)

M. Kull (Ulm, Germany )

17:15

## Poster, Foyer 2. OG

### Innovation and Novelty

## P2Y6 depletion enhances metabolic activity and ameliorates outcome of high fat diet induced obesity in mice

J. Merz (Freiburg, Deutschland)

P. Stachon (Freiburg, Deutschland)

P. Albrecht (Freiburg, Deutschland)

F. Ünal (Freiburg, Deutschland)

S. von Garlen (Freiburg, Deutschland)

A. Heidenreich (Freiburg, Deutschland)

N. Hoppe (Freiburg, Deutschland)

B. Duffner (Freiburg, Deutschland)

C. Bode (Freiburg, Deutschland)

A. Zirlik (Freiburg, Deutschland)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Development and application of methods for the selective measurement of the human single amino acid exchange variant factor IX Padua

A. Weber (Vienna, Austria)  
A. Engelmaier (Vienna, Austria)  
D. Voelkel (Orth, Austria)  
R. Pachlinger (Orth, Austria)  
F. Scheiflinger (Vienna, Austria)  
H. Rottensteiner (Vienna, Austria)

Fucoidans inhibit cellular responses to the chemokine IL-8 and the anaphylatoxin C5a better than heparin

S. Alban (Kiel, Germany)  
K. Ehrig (Kiel, Germany)  
I. Liewert (Kiel, Germany)

17:15

Poster, Foyer 2. OG

Late-breaking posters

The effect of storage on the platelet hemostatic activity

E. V. Roitman (Moscow, Russia)  
I. M. Kolesnikova (Moscow, Russia)

Evaluation of platelet hemostatic capacity using new thromboelastography-based assay

E. V. Roitman (Moscow, Russia)  
I. M. Kolesnikova (Moscow, Russia)

Blood rheology factors for thrombus formation in some oncohematological diseases

E. V. Roitman (Moscow, Russia)  
I. M. Kolesnikova (Moscow, Russia)

Identification of novel mutations in FGA fibrinogen gene in Pakistani congenital afibrinogenemia patients

T. Khan (Karachi, Pakistan)  
A. Naz (Karachi, Pakistan)  
A. Biswas (Bonn, Germany)  
N. Ahmed (Lahore, Pakistan)  
S. Ahmed (Karachi, Pakistan)  
T. Shamsi (Karachi, Pakistan)  
J. Oldenburg (Bonn, Germany)



# 61<sup>ST</sup> ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

## Quantification of the antimetastatic effects of heparins by Single-cell force spectroscopy

H. Schillers (Münster, Germany)

A. Schmidt (Münster, Germany)

S. Bobe (Münster, Germany)

N. Martins-Castanheira (Münster, Germany)

## Gene polymorphism of plasminogen activator inhibitor-1 is a risk factor of thrombosis in patients with antiphospholipid syndrome

L. Mukhametova (Moscow, Russia)

R. Aisina (Moscow, Russia)

T. Reshetnyak (Moscow, Russia)

L. Patrushev (Moscow, Russia)

K. Gershkovich (Moscow, Russia)

## Combinations of recombinant staphylokinase (STA) and single-chain urokinase-type plasminogen activator (scuPA) induce synergistic thrombolysis in vitro

R. Aisina (Moscow, Russia)

L. Mukhametova (Moscow, Russia)

K. Gershkovich (Moscow, Russia)

S. Varfolomeyev (Moscow, Russia)

## Positive and negative role of oxidative stress in the prognosis of patients with gastric cancer.

M. Kedzierska (Lodz, Poland)

J. Kolodziejczyk-Czepas (Lodz, Poland)

J. Jakubik (Lodz, Poland)

J. Piekarski (Lodz, Poland)

A. Jeziorski (Lodz, Poland)

P. Nowak (Lodz, Poland)

P. Potemski (Lodz, Poland)

18:00

## Poster, Foyer 2. OG

Presentation of Best Poster Awards